SCHEDULE: Horizon Ridge & Shan Xie Report 9.97% Stake in Universe Pharmaceuticals

Horizon Ridge Limited and Shan Xie have jointly filed a Schedule 13G, reporting beneficial ownership of 9.97% of Universe Pharmaceuticals INC's Class A ordinary shares.

Summary

• Horizon Ridge Limited, a company organized in the British Virgin Islands and wholly owned by Shan Xie, has acquired a significant stake in Universe Pharmaceuticals INC.
• The filing indicates shared voting and dispositive power over 499,424 Class A ordinary shares.
• This ownership stake represents 9.97% of the total outstanding Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026.
• The filing is made under Rule 13d-1(b) and certifies that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant operational or financial updates.

Positives

• Significant ownership stake acquired by Horizon Ridge Limited and Shan Xie, potentially indicating confidence in the company's future.
• The filing explicitly states the shares were not acquired to influence control, suggesting a passive investment approach.

Negatives

• The filing does not provide operational or financial performance details, limiting insight into the company's current health.
• The exact date of acquisition or the purchase price of the shares is not disclosed in this filing.

Risks

• Potential for increased market scrutiny due to a significant block holder acquiring a near 10% stake.
• Future actions of the new significant shareholder could impact share price volatility.

Future Outlook

No forward-looking statements or specific future guidance are provided in this Schedule 13G filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically report passive investments by institutional investors or individuals. The acquisition of a 9.97% stake by Horizon Ridge Limited and Shan Xie in Universe Pharmaceuticals suggests a notable shift in the company's shareholder composition, which could be a precursor to further strategic developments or simply a passive investment.

Stakeholder Impact

• Shareholders: May observe increased volatility or strategic shifts in Universe Pharmaceuticals INC due to the new significant stakeholder.
• Management: May need to engage with Horizon Ridge Limited and Shan Xie regarding their investment intentions.

Next Steps

• Monitor future filings from Horizon Ridge Limited and Shan Xie for any changes in beneficial ownership.
• Observe Universe Pharmaceuticals INC's strategic responses or communications regarding its new significant shareholder.

Key Dates

Recommendation

The filing indicates a significant passive investment, but lacks operational or financial data to support a buy or sell decision. A 'hold' recommendation is appropriate pending further information on the company's performance and the investor's long-term strategy.

Keywords

Universe Pharmaceuticals, Schedule 13G, Beneficial Ownership, Horizon Ridge Limited, Shan Xie, Class A ordinary shares, Significant Stakeholder